The U.S. atherosclerosis treatment market is driven by a high prevalence of cardiovascular diseases, pharmaceutical advancements, an aging population, lifestyle risks, and government health initiatives, with a 2.3% CAGR (2025-2035).
NEWARK, DE / ACCESS Newswire / February 25, 2025 / The global atherosclerosis market is on track to attain USD 47,637.4 million by 2025, expanding at a compound annual growth rate (CAGR) of 2.7%, reaching USD 62,180.3 million by 2035. The revenue generated by therapeutic apheresis in 2024 was approximately USD 46,430.2 million, highlighting the market's strong foothold in cardiovascular disease management.
Atherosclerosis is the shrinking of a vein caused by plaque accumulation. Atherosclerosis is a kind of arteriosclerosis (stiffening or solidifying of the artery walls). The sickness disrupts the flow of blood throughout the body, posing significant cardiovascular complications.
Atherosclerosis starts when the endothelium is damaged, allowing LDL cholesterol to accumulate in the arterial wall. To clean up the cholesterol, the body sends macrophage white platelets.
However, the cells occasionally halt at the impacted spot. After a while, this resulted in plaque formation, which was composed of bad cholesterol (LDL cholesterol) and macrophage white platelets. The plaque obstructs the corridor, disrupting the flow of blood throughout the body. This may result in blood clusters, which can lead to life-threatening diseases such as heart attack, stroke, and other cardiovascular disorders.
Aside from age, the following factors increase the risk of atherosclerosis: high blood pressure, high cholesterol, diabetes, obesity, smoking or other tobacco use, family history of early heart disease, lack of exercise, and a poor diet..
Stay Informed on Key Market Changes: Get a Sample Report! https://www.futuremarketinsights.com/report-sample#5245502d47422d32353233
What Are the Challenges Faced by the Atherosclerosis Market?
Absence of Definitive Therapy to Stymie the Market Growth
New competitors in the atherosclerosis market have demonstrated increased adequacy and security profiles, as well as a reduction in CHD risk factors. Atherosclerosis, also known as coronary artery disease, has two treatment options: coronary artery bypass grafting (CABG) and angioplasty.
The CAD death rate is relatively high when compared to other diseases caused by coronary events associated with CAD, such as myocardial infections (MI), angina, and strokes. As a result, the antidote to such situations remains an unexplored area of research and development for pharmaceutical companies seeking to bring breakthrough drugs to market.
However, the absence of definitive therapy, side effects and limited efficacy of current medications, and reliance on symptom-based treatment in certain situations are likely to hinder revenue growth in the atherosclerosis market throughout the forecast period.
Moreover, the high cost of the treatment is expected to hamper the market's growth rate. The atherosclerosis market is estimated to be challenged by a lack of skilled professionals and a dearth of healthcare infrastructure in developing economies. Furthermore, strict regulatory policies and a lack of public awareness might restrain and impede market growth during the forecast period.
Challenges and Opportunities: Atherosclerosis Market from 2025 to 2035
Challenges in the Atherosclerosis Market
High Treatment Costs - The cost associated with advanced biologics, gene therapies, and long-term medication regimens remains a key barrier, limiting patient access.
Regulatory Hurdles - Stringent regulatory pathways for novel drug approvals may delay commercialization and market entry of innovative therapies.
Side Effects of Current Therapies - Statins and PCSK9 inhibitors, while effective, can cause adverse effects, impacting patient adherence and treatment efficacy.
Limited Awareness and Screening - In low- and middle-income countries, limited access to diagnostic tools and preventive healthcare initiatives hampers early detection and intervention.
R&D Challenges - The complexity of atherosclerosis pathophysiology presents difficulties in drug development, requiring significant investment in research and clinical trials.
Opportunities Driving Market Growth
Advancements in Precision Medicine - The integration of genetic profiling and biomarker-based diagnostics is enabling personalized treatment approaches, improving therapeutic outcomes.
Emerging RNA-Based Therapies - The rise of RNA therapeutics, such as small interfering RNAs (siRNAs) targeting lipid metabolism, offers new avenues for disease management.
Expanding Role of AI and Digital Health - Artificial intelligence and digital health platforms are revolutionizing early detection, risk assessment, and patient monitoring.
Increased Investment in Cardiovascular Research - Growing collaborations between pharmaceutical companies and research institutions are accelerating innovation in drug discovery.
Government Initiatives and Public Health Campaigns - Increased awareness campaigns and screening programs are expected to improve early diagnosis and prevention efforts globally.
"Atherosclerosis treatment is evolving rapidly with the integration of precision medicine and novel therapeutic approaches. The introduction of PCSK9 inhibitors and advancements in gene editing signify a major shift toward long-term disease management. As pharmaceutical companies continue to invest in cutting-edge biotechnologies, we anticipate a sustained growth trajectory in the market," says Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.
Elevated Market Interest: Delve into In-Depth Trends and Insights with Our Full Report! https://www.futuremarketinsights.com/reports/atherosclerosis-market
Category-wise Insights
Which Therapy Segment is Gaining Traction in the Atherosclerosis Market?
Cholesterol-lowering Medications to Remain Most Sought After
Statins and fibrates are examples of cholesterol-lowering medications. The segment's dominance is attributed to the rising prevalence of cardiovascular disease, high cholesterol, and obesity worldwide. According to the World Health Organization, 40 million children under the age of five were overweight or obese in 2018.
A higher intake of energy-dense foods high in fat and sugars, as well as an increase in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanization, are factors driving high cholesterol rates and, ultimately, boosting segment growth.
In addition, the approval of new cholesterol-lowering medicines is boosting segment growth. For example, the drugs alirocumab (Praluent) and evolocumab (Repatha) belong to a new class of drugs known as PCSK9 inhibitors, which reduce harmful LDL cholesterol levels by more than 50%. Novel treatment drugs of this type boost segment growth. The growing patient pool and increased approvals for new medicines boost segment growth.
Which is the Leading Distribution Channel of the Atherosclerosis Market?
Retail Pharmacies are expected to Continue to Be a Beneficial Distribution Channel
As per Future Market Insights (FMI), the retail pharmacies segment is expected to become the primary point-of-sale channel for atherosclerosis as they expand to even the most remote locations, making it easier for consumers to present prescriptions and purchase drugs.
Furthermore, retail pharmacists provide more consultative services regarding drug administration routes and potential side effects. Retail pharmacies carry a variety of brands, making them a good place for patients to shop. Hospital pharmacists, on the other hand, operate in a more clinic-oriented manner, having frequent contact with doctors and nurses, and they manage their inventories with only specific brands.
Company Profile
GlaxoSmithKline plc
AstraZeneca
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd.
Isis Pharmaceuticals, Inc.
Anthera Pharmaceuticals
Novartis AG
Sanofi
Johnson and Johnson
Bayer AG
The Medicine Company
Cardium Therapeutics
Advantage Healthcare Insights to Outpace Competitors! https://www.futuremarketinsights.com/industry-analysis/therapy-area
Segmentation Insights: Unlocking Growth Potential Across Key Industry Areas
By Therapy:
Drug Type and Interventional Devices
By Indication:
Atherosclerosis, Medial Calcificsclerosis, Arteriolosclerosis and Mönckeberg Arteriosclerosis
By Distribution Channel:
Hospital, Cardiac Catheterization Labs, Retail Pharmacies, Online Pharmacies
By Region:
North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East & Africa
Explore FMI's Related Ongoing Coverage on Healthcare Market Insights Domain:
The leukemia therapeutics treatment market size is projected to expand from USD 17.4 billion in 2025 to a potential USD 33.1 billion by 2035, at a compound annual growth rate (CAGR) of 6.6% The rising use of CAR-T cell therapy, monoclonal antibodies, and novel chemotherapy regimens are changing treatment paradigms in leukemia.
The global sales of prostate cancer are estimated to be worth USD 12.9 billion in 2025 and anticipated to reach a value of USD 29.2 billion by 2035. Sales are projected to rise at a CAGR of 8.5% over the forecast period between 2025 and 2035. The revenue generated by prostate cancer in 2024 was USD 11.9 billion.
The global endometriosis treatment market share as anticipated for 2025 was to be valued at USD 3,727.4 million and by 2035 was projected to amount to USD 6,297.2 million. Such sales would consider a CAGR increasing by 5.4% between 2025 and the end of the forecast period in 2035.
Globally, they estimate opioid use disorder treatment market demand in 2025 to be USD 856.9 million, and it is anticipated to grow to USD 1,747.0 million by 2035. It is expected to grow at an annual growth rate of 7.4% from 2025 to 2035.
The global rare neurological disease treatment market growth is estimated to be worth USD 19,949.6 million in 2025 and anticipated to reach a value of USD 40,671.5 million by 2035. Sales are projected to rise at a CAGR of 7.4% over the forecast period between 2025 and 2035.
The global hypoparathyroidism treatment market trends is estimated to be worth USD 785.7 million by 2025 and is projected to reach a value of USD 1,152.9 million by 2035, reflecting a CAGR of 3.9% over the assessment period 2025 to 2035.
The global biliary tract cancers treatment market outlook reached USD 343.4 Million in 2024, and the market is expected to reach USD 372.5 million in 2025. In the projection period of 2025 to 2035, sales of global biliary tract cancers treatment are forecasted to increase at 8.2% CAGR and is expected to reach up to a market size of USD 824.2 million by the end of 2035.
The global anti-osteoporosis fracture healing market overview is currently valued at around USD 15,612.4 million, and is anticipated to progress at a CAGR of 4.2% to reach USD 23,558.5 million by 2035.
The global allergy immunotherapy market analysis is valued at USD 1,942.1 million in 2025, registering Y-o-Y growth of 7.9% attaining market value of USD 4,161.9 million by 2035. The revenue generated by allergy immunotherapy in 2024 was USD 1,840.8 million.
The global acetaminophen market forecast is estimated to be worth USD 10,905.7 million in 2025 and anticipated to reach a value of USD 16,333.5 million by 2035. Sales are projected to rise at a CAGR of 4.1% over the forecast period between 2025 and 2035.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn | Twitter | Blogs | YouTube
SOURCE: Future Market Insights Inc.
View the original press release on ACCESS Newswire
